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Abstract: Diabetes mellitus (DM) is a complex disease which currently affects more than 460 million
people and is one of the leading cause of death worldwide. Its development implies numerous
metabolic dysfunctions and the onset of hyperglycaemia-induced chronic complications. Multiple
ligands can be rationally designed for the treatment of multifactorial diseases, such as DM, with the
precise aim of simultaneously controlling multiple pathogenic mechanisms related to the disease and
providing a more effective and safer therapeutic treatment compared to combinations of selective
drugs. Starting from our previous findings that highlighted the possibility to target both aldose
reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated
in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-
3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the
effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands
(DMLs). Out of the tested compounds, 4f exhibited well-balanced AR/PTP1B inhibitory effects at low
micromolar concentrations, along with interesting insulin-sensitizing activity in murine C2C12 cell
cultures. The SARs here highlighted along with their rationalization by in silico docking experiments
into both target enzymes provide further insights into this class of inhibitors for their development
as potential DML antidiabetic candidates.
Keywords: multi-target ligands; diabetes mellitus; aldose reductase; protein tyrosine phosphatase
1B; 4-thiazolidinones; molecular docking
1. Introduction
In the last decade, the design and discovery of multi-target-directed ligands has
emerged as a modern promising strategy to develop new drugs aimed to the treatment
of multifactorial diseases, such as diabetes, cancer, infectious diseases, cardiovascular
and neurodegenerative disorders. Therapies based on a single-target-directed agent may
be insufficient for the management of these complex pathologies, thus combinations of
different drugs generally represent therapeutic regimens necessary in order to achieve a
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higher efficacy. However, combination therapies may involve pharmacokinetics, toxicity or
patient compliance problems.
Therefore, recently multi-targeted ligands have attracted great interest in medicinal
chemistry as a valuable alternative to combinations of single-targeted drugs. In particu-
lar, designed multiple ligands (DMLs) are compounds rationally designed to modulate
two or more selected targets simultaneously and, thus, to achieve pharmacological effects
favourable for the efficient management of multifactorial pathologies. Growing evidence in-
dicates that DMLs may be endowed with enhanced efficacy and improved safety compared
to drug combinations, especially in long-term therapies [1–4].
A drug design strategy frequently used to obtain DMLs starts from the knowledge
of the distinct pharmacophores of agents active on each of the individual targets and
consists in the integration of these pharmacophores into a single structure to obtain hybrid
molecules. Hybridization should be carried out in such a way that the pharmacophoric
elements inserted in a resulting DML maintain the ability to interact with specific sites of
the different selected targets, thus producing simultaneously the desired effects. In order
to obtain molecules endowed with appropriate drug-like properties, it is often preferred
to partially overlap the different pharmacophores, by using or merging them. However,
by applying the different possible approaches for the design of DMLs, it is quite likely
to achieve lead compounds endowed with high potency towards only one of the desired
targets, with less effect on the others; therefore, it is often necessary to carry out a balancing
process, using structural modifications of the lead compound, aimed to modulate and
balance the activity towards the selected targets until to reach an optimal ratio [1,4].
Recently we have reported an initial investigation on 4-thiazolidinone derivatives
active as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the
context of our search for new candidates for the treatment of type 2 diabetes mellitus
and its complications [5]. Diabetes mellitus (DM) is a complex chronic metabolic disease
which represents a global severe health problem. It has been estimated that currently
more than 460 million people are affected by DM worldwide and the prevalence of this
disease is expected to increase to about 700 million by 2045 [6,7]. Moreover, it is estimated
that about 10% of the total deaths in the world are linked to DM. Glycaemic control
is the main goal in DM care and oral antihyperglycaemic drugs or insulin therapy are
commonly used for this purpose. However, when not adequately treated, diabetic patients
may be chronically exposed to unnatural glucose fluctuations, which induce cell damage
and trigger a low-grade systemic inflammation, ultimately causing the onset of severe
long-term complications, such as micro/macroangiopathies, neuropathy, nephropathy
and cardiovascular dysfunctions. Therefore, to obtain an effective glycaemic control
and prevent chronic complications, the standard therapeutic treatment of DM is often
represented by drug cocktails. Consequently, it is conceivable that different key pathogenic
events involved in DM could be advantageously addressed by DMLs [8,9].
On these bases, in the context of a search for new DMLs as potential antidiabetic agents,
we selected as targets aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B),
two enzymes differently involved in the development of DM and its complications.
AR (E.C. 1.1.1.21) is an aldo-keto reductase capable to catalyse the reduced nicoti-
namide adenine dinucleotide phosphate (NADPH)-dependent reduction of a variety of
aldehydes, including aldoses. Under hyperglycaemic conditions, such as in DM, an in-
creased flux of glucose through the polyol pathway occurs. AR catalyses the first and
rate-limiting step of this metabolic pathway, by reducing glucose to sorbitol which is
then oxidized to fructose by sorbitol dehydrogenase. The increased glucose metabolism
through the polyol pathway causes osmotic imbalance, decreases antioxidant cellular
defence and promotes glycation and inflammatory events, thus leading to tissue dam-
age which is responsible for the development of diabetic chronic complications [10,11].
AR is also capable to reduce reactive unsaturated aldehydes, derived from oxidative
stress-induced lipid peroxidation and their glutathione-conjugates, such as 4-hydroxy-
2,3-nonenal (HNE), thus participating in the detoxification processes of toxic aldehydes.
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However, the AR-catalysed reduction of the adduct glutathione-HNE (GS-HNE) gener-
ates 3-glutathionyl-1,4-dihydroxynonane (GS-DHN) which is a potent pro-inflammatory
molecule; inflammatory events triggered by GS-DHN are strictly related to the develop-
ment of cellular and vascular damage responsible for diabetic complications. On these
bases, AR inhibitors are actively searched to prevent and control the onset and progression
of hyperglycaemia-induced pathologies associated to DM and also as potential agents for
other inflammatory diseases [11–13].
Numerous evidences have undoubtedly demonstrated that PTP1B (E.C. 3.1.3.48) is
involved in the development of insulin-resistance, which is a characteristic condition in
type 2 DM (T2DM). This protein tyrosine phosphatase acts as a major negative regulator
of insulin signalling, by dephosphorylating specific phosphotyrosine residues of the acti-
vated insulin receptor and insulin receptor substrate proteins and thus attenuating insulin
signalling pathways. PTP1B has been shown to be overexpressed in T2DM and in other
pathologies associated with insulin resistance, such as obesity [14–16]. The deregulation of
this phosphatase is also strictly linked to a chronic low grade inflammation [17], related to
insulin resistance and DM. The inhibition or genetic ablation of PTP1B can enhance insulin
receptor phosphorylation and improve cellular response to insulin, thus counteracting
insulin resistance and increasing glucose uptake into cells [18,19]. Therefore, PTP1B is
considered a validated target to develop inhibitors as drug candidates for the treatment of
T2DM [20–22].
On these bases, both PTP1B and AR can be assumed as attractive molecular targets
for the design of DMLs capable to control simultaneously different cellular mechanisms
underlying the development of both T2DM and its complications. However, this research
is still in its infancy and, so far, only few dual ALR2/PTP1B inhibitors have been reported,
among which some natural compounds such as berberine [23,24].
Although these two enzymes belong to different families of proteins, the knowledge of
their active sites and the structure-activity relationships (SARs) of inhibitors of each of these
targets highlights several shared structural features that enable the design of dual inhibitors
by merging the respective pharmacophores. In particular, our previous studies on different
4-thiazolidinone derivatives, which were investigated as AR or PTP1B inhibitors (Figure 1),
evidenced that the pharmacophores of both classes of inhibitors comprise a polar head
in position 3 of the heterocyclic core, including an acidic or H-bond acceptor group and
a lipophilic portion in position 5, containing one or more suitably substituted aromatic
moieties [25–38].
Therefore, starting from a knowledge-based approach, recently we merged (5-arylidene-
4-oxothiazolidin-3-yl)acetic acid derivatives, which are endowed with excellent AR in-
hibitory activity and 4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acids, which
we identified as potent PTP1B inhibitors, to obtain a series of new 4-thiazolidinone
derivatives (1, 2, Figure 1) that were evaluated as dual inhibitors of both human AR
and PTP1B enzymes [5]. Out of them, we identified two analogues, that is, (4-oxo-5-
{[3-(2-phenylethoxy)pheny]lmethylidene}-2-thioxothiazolidin-3-yl)acetic acid (2e) and the
corresponding 2,4-thiazolidinedione counterpart 1e (Figure 1), which exhibited potent AR
inhibitory effects along with appreciable PTP1B inhibitory capability. Kinetic and in silico
docking studies clearly indicated that these compounds behave as reversible inhibitors of
both human AR and PTP1B, displaying an uncompetitive and non-competitive mechanism
of action, respectively [5].
The opportunity to design inhibitors capable to bind non-catalytic regions of both AR
and PTP1B is a promising tool for the discovery of new DMLs in this context. Therefore, in
order to gain further insights into structural requirements for dual AR/PTP1B inhibition,
starting from the SARs acquired from compounds 1–2, we designed and synthesised
3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids 3a–f and 4a–f and 4-(5-arylidene-
2,4-dioxothiazolidin-3-yl)-2-butenoic acids 5a–e (Figure 1). In these newly-synthesised
compounds, we modified the carboxylic chain on N-3, with the aim of balancing the
inhibitory effects against the two target enzymes. The elongation of this carboxylic chain
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might be beneficial to ensure further effective interactions with both target enzymes, as
suggested by our previous molecular docking investigation.
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l i , -
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point for hit-to-lead optimization.
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bovine lens R had revealed no inhibition, probably because the bulky benzoic substituent
on the N-3 might prevent the interaction with the AR active site. Now, we decided to assess
if 2-butenoic acid derivatives are useful to achieve both PTP1B and AR inhibition since the
2-butenoic residue could be assumed as a simpler open mimetic of the benzoic acid residue
capable to interact effectively with PTP1B and, at the same time, could bind to AR.
In the 5-arylidene moiety of compounds 3–5, the structural features, such as two
differently linked aromatic rings that had proven to be effective for dual AR/PTP1B
inhibition [5] were maintained (Table 1).
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X R Ar ARIC50 (µM)
PTP1B
IC50 (µM)
3a O (CH2)2COOH 3-OC6H5-C6H4 11.9 ± 0.9 79% at 50 µM
3b O (CH2)2COOH 4-OC6H5-C6H4 43.8 ± 7.1 56% at 50 µM
3c O (CH2)2COOH 3-OCH2C6H5-C6H4 14.3 ± 1.0 76% at 50 µM
3d O (CH2)2COOH 4-OCH2C6H5-C6H4 35.7 ± 3.0 77% at 50 µM
3e O (CH2)2COOH 3-OCH2CH2C6H5-C6H4 27.9 ± 3.1 64% at 50 µM
3f O (CH2)2COOH 4-OCH2CH2C6H5-C6H4 50.2 ± 4.6 46% at 50 µM
4a S (CH2)2COOH 3-OC6H5-C6H4 2.2 ± 0.1 34.1 ± 0.5
4b S (CH2)2COOH 4-OC6H5-C6H4 7.6 ± 0.6 29.5 ± 0.4
4c S (CH2)2COOH 3-OCH2C6H5-C6H4 3.8 ± 0.1 42.8 ± 0.7
4d S (CH2)2COOH 4-OCH2C6H5-C6H4 8.4 ± 0.7 34.9 ± 0.7
4e S (CH2)2COOH 3-OCH2CH2C6H5-C6H4 2.3 ± 0.1 55.5 ± 0.8
4f S (CH2)2COOH 4-OCH2CH2C6H5-C6H4 5.3 ± 0.4 12.7 ± 0.3
5a O CH2CH=CHCOOH 3-OC6H5-C6H4 3.9 ± 0.2 42.1 ± 0.3
5b O CH2CH=CHCOOH 4-OC6H5-C6H4 84% at 10 µM 39.7 ± 0.1
5c O CH2CH=CHCOOH 4-C6H5-C6H4 88% at 5 µM 34.8 ± 0.5
5d O CH2CH=CHCOOH 1-naphthyl 3.7 ± 0.2 40.3 ± 0.5
5e O CH2CH=CHCOOH 2-naphthyl 86% at 10 µM 37.1 ± 0.4
Epalrestat 0.102 ± 0.005
Vanadate 0.4 ± 0.01
a IC50 (µM) or % enzyme residual activity at the indicated concentration. Values are expressed as the mean ±
S.E.M (see methods for details).
Calculated physicochemical and pharmacokinetic parameters of the synthesised com-
pounds 3–5 indicated good drug likeness for these molecules and suggested that high oral
bioavailability could be expected for all of them (see Supplementary Table S1).
In addition, although 2-thioxothiazolidinones 4a–d are present in the literature [39–41],
to our knowledge none of them had ever been evaluated as AR or PTP1B inhibitor so far.
2. Results and Discussion
2.1. Chemistry
3-(5-Arylidene-2,4-dioxothiazolidin-3-yl)propanoic acids (3a–f) and 4-(5-arylidene-
2,4-dioxothiazolidin-3-yl)-2-butenoic acids (5a–e) were prepared through multi-step pro-
cedures starting from 5-arylidene-2,4-thiazolidinediones 6a–i (Scheme 1). Precursor com-
pounds 6 were prepared with good yields by the Knoevenagel condensation of commercial
2,4-thiazolidinedione with appropriate aldehydes, in refluxing ethanol and in the presence
of piperidine as a base, according to a procedure that we had previously reported [26,37].
Subsequently, the reaction of the appropriate compound 6 with 3-chloropropanoic acid
in refluxing acetone and in the presence of potassium carbonate, followed by a work-up
in acidic medium and recrystallization from methanol, provided pure 3-(5-arylidene-2,4-
dioxothiazolidin-3-yl)propanoic acids (3a–f) in high yields (Scheme 1).
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The reaction of precursor 2,4-thiazolidinediones 6 with methyl 4-bromocrotonate
in refluxing acetone provided 4-(5-arylidene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid
methyl esters, which were hydrolysed in an acidic medium to generate the corresponding
acids 5a–e (Scheme 1).
The synthetic procedure to obtain 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)propanoic
acids (4a–f) included the preparation of precursor 7 (Scheme 2). Compound 7 was synthe-
sised by the cyclization of β-alanine with carbon disulphide and sodium bromoacetate,
in the presence of sodium hydroxide, in aqueous solution. Subsequently, the desired
3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)propanoic acids (4a–f) were obtained by the
Knoevenagel condensation of 3-(4-oxo-2-thioxothiazolidin-3-yl)propanoic acid (7) with the
appropriate aldehyde, in refluxing acetic acid in the presence of sodium acetate (Scheme 2).




Scheme 1. Synthesis of 3-(5-arylidene-2,4-dioxothiazolidin-3-yl)propanoic acids 3a–f and 4-(5-arylidene-2,4-dioxothiazol-
idin-3-yl)-2-butenoic acids 5a–e. 
Subsequently, the reaction of the appropriate compound 6 with 3-chloropropanoic 
acid in refluxing acetone and in the presence of potassium carbonate, followed by a work-
up in acidic medium and recrystallization from methanol, provided pure 3-(5-arylidene-
2,4-dioxothiazolidin-3-yl)propanoic acids (3a–f) in high yields (Scheme 1).  
The reaction of precursor 2,4-thiazolidinediones 6 with methyl 4-bromocrotonate in 
refluxing acetone provided 4-(5-arylidene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid me-
thyl esters, which were hydrolysed in an acidic medium to generate the corresponding 
acids 5a–e (Scheme 1). 
The synthetic procedure to obtain 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)pro-
panoic acids (4a–f) included the preparation of precursor 7 (Scheme 2). Compound 7 was 
synthesised by the cyclization of β-alanine with carbon disulphide and sodium bromo-
acetate, in the presence of sodium hydroxide, in aqueous solution. Subsequently, the de-
sired 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)propanoic acids (4a–f) were obtained 
by the Knoevenagel condensation of 3-(4-oxo-2-thioxothiazolidin-3-yl)propanoic acid (7) 
with the appropriate aldehyde, in refluxing acetic acid in the presence of sodium acetate 
(Scheme 2). 
. t esis of 3-(5-arylidene-2,4-diox thiazolidin-3-yl)pro anoic acids 3a–f and 4-(5-arylidene-2,4-dioxothiaz lidin
-3-yl)-2-butenoic acids 5a–e.




Scheme 2. Synthesis of 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)propanoic acids 4a–f. 
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[25,42]. All 1H-NMR spectra showed only one singlet attributable to the resonance of the 
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1H-NMR spectra of propanoic acids 3 and 4 exhibited two characteristic triplets at 
2.57–2.63 ppm and 3.84–4.23 ppm (J = 7.2–7.5 Hz) due to the resonance of the methylene 
protons of the propanoic chain on N-3. In the spectra of compounds 3e,f and 4e,f, two 
additional triplets (with smaller coupling constant values of 6.8–6.9 Hz) are present at 
3.05–3.06 ppm and 4.25–4.29 ppm, originated from the resonance of the ethoxy chain in-
cluded in the 5-arylidene portion. 
In 1H-NMR spectra of compounds 5, the resonance of 2-butenoic chain gave rise to 
characteristic signals, that is, a doublet at 4.45–4.47 attributable to NCH2 protons and two 
multiplets in the range 5.87–6.83 ppm originated by CH=CH.  
In 13C-NMR spectra, the singlets produced by the resonance of the carbonyl groups 
in the range 165.8–173.1 ppm are diagnostic as well as, in the case of compounds 4, the 
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2.2. AR and PTP1B Inhibition 
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2.57–2.63 pp and 3.84–4.23 pp (J = 7.2–7.5 z) due to the resonance of the ethylene
protons of the propanoic chain on -3. In the spectra of co pounds 3e,f and 4e,f, t o
additional triplets (with smaller coupling constant values of 6.8–6.9 Hz) are present at 3.05–
3.06 ppm and 4.25–4.29 ppm, originated from the resonance of the ethoxy chain included
in the 5-arylidene portion.
In 1H-NMR spectra of compounds 5, the resonance of 2-butenoic chain gave rise to
characteristic signals, that is, a doublet at 4.45–4.47 attributable to NCH2 protons and two
multiplets in the range 5.87–6.83 ppm originated by CH=CH.
In 13C-NMR spectra, the singlets produced by the resonance of the carbonyl groups in
the range 165.8–173.1 ppm are diagnostic as well as, in the case of compounds 4, the signal
at 193.7–194.2 ppm attributable to the thiocarbonyl group.
2.2. AR and PTP1B Inhibition
The inhibitory effects of compounds 3–5 were assessed in vitro against both human
recombinant AR, by using L-idose as substrate and epalrestat as the reference drug and
human recombinant PTP1B, by using p-nitrophenyl phosphate as substrate and sodium
metavanadate as the reference drug. Table 1 reports the data resulting from these assays
for the two target enzymes.
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Compounds 5a–c had already been evaluated against bovine lens AR, using D,L-
glyceraldehyde as a substrate [26]; here, they were assayed against the human enzyme
with L-idose as a substrate to obtain comparable data useful for the SAR study.
All tested 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids 3a–f and 4a–f showed
good inhibitory properties against human AR, with IC50 values in the mid- and low-
micromolar range (Table 1). Their AR inhibitory potency proved to be markedly influenced
by the substituents in the positions 2 and 3 of the thiazolidinone scaffold and, to a lesser
extent, by the nature of the 5-arylidene moiety. 3-(5-Arylidene-4-oxo-2-thioxothiazolidin-
3-yl)propanoic acids 4 exhibited IC50 values in the low micromolar range (<10 µM); out
of them, 4a and 4e proved to be the most potent inhibitors of human AR, with IC50
values of 2.2 µM and 2.3 µM, respectively. 2,4-Thiazolidinedione analogues 3 showed
the appreciable capability to inhibit the enzyme, especially compounds 3a and 3c, which
displayed IC50 values slightly higher than 10 µM (Table 1). On the whole, 2-thioxo-4-
thiazolidinone derivatives 4a–f proved to be from 4- to 12-fold more efficient AR inhibitors
than the corresponding 2,4-thiazolidinones 3a–f (Table 1), as already observed for other
analogues [32].
However, compared with the parent acetic acids (compounds 1, 2 Figure 1), the
elongation of the carboxylic chain on N-3 from two to three carbon atoms appeared to be
responsible for a significant decrease in AR inhibitory potency for both 3-(5-arylidene-4-
oxo-2-thioxothiazolidin-3-yl)propanoic acids 4 and their 2,4-thiazolidinedione analogues 3.
The IC50 values obtained for compounds 4a–f revealed that they were from 40-fold to more
than 100-fold less potent than acetic acid analogues 2. Analogously, compounds 3e and 3f
showed IC50 values two orders of magnitude higher than those of the corresponding acetic
acid derivatives 1 [5].
The influence exerted on the AR inhibitory potency by the nature of the moiety in
position 5 of the heterocyclic core did not appear to be marked; in fact, we observed
that the IC50 values fall within a relatively narrow range for each series 3 and 4 (Table 1).
However, in both series 3 and 4, compounds bearing a substituent in the meta position
of the 5-benzylidene ring (3a, 3c, 3e and 4a, 4c, 4e) exhibited better activity than the para-
substituted isomers (3b, 3d, 3f and 4b, 4d, 4f, respectively), confirming a SAR that we had
observed in the previously investigated 4-thiazolidinones active as AR inhibitors [25–32].
Among 2-butenoic acid derivatives 5, compounds 5a and 5d exhibited significant capability
to inhibit human AR with IC50 values of 3.9 µM and 3.7 µM, respectively, whereas the
other analogues (5b, 5c, 5e) produced scarce inhibition at concentrations up to 10 µM
(Table 1). It is worthwhile to notice that 5a had shown very scarce inhibitory activity
towards bovine lens AR, in the presence of glyceraldehyde as substrate, whereas 5b and 5c
were almost inactive towards both bovine and human enzymes with glyceraldehyde and
idose as substrate, respectively [26]. These data confirmed previous observations that both
the enzymatic source and the substrate used are relevant factors affecting AR inhibitor
susceptibility [43,44].
The inhibitory activity towards human PTP1B of compounds 3–5 was generally found to
be lower than towards human AR. However, all 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-
yl)propanoic acids (4a–f) and 4-(5-arylidene-2,4-dioxothiazolidin-3-yl)-2-butenoic acids (5a–e)
displayed interesting PTP1B inhibitory properties, with mid-micromolar IC50 values (Table 1).
Among them, 3-[4-oxo-{5-[4-(2-phenylethoxy)phenyl]methylidene}-2-thioxothiazolidin-3-yl]
propanoic acid (4f) was shown to be the most effective PTP1B inhibitor (IC50 = 12.7 µM). In
compounds 4, we found that selected substituents in the para position of the 5-benzylidene
ring improved moderately the inhibitory effects, compared to the meta isomers.
In addition, it is worthwhile to notice that, in comparison with the previously investi-
gated acetic analogues 2, the elongation of the carboxylic chain on N-3 generally improved
the PTP1B inhibitory activity, as demonstrated by propanoic derivatives 4; in fact, we found
that compounds 4a, 4b, 4d and 4f were from 2- to 4-fold more potent PTP1B inhibitors
than their acetic counterparts [5]. On the other hand, compared with the corresponding
2-thioxo-4-thiazolidinones 4, the PTP1B inhibitory ability of 2,4-thiazolidinediones 3 was
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shown to be significantly lower (Table 1), highlighting that 3-(4-oxo-2-thioxothiazolidin-
3-yl)]propanoic moiety is more favourable for PTP1B inhibition. However, out of the
tested 2,4-thiazolidinedione derivatives, the replacement of the propanoic chain on N-3
(compounds 3) with a 2-butenoic residue (compounds 5) provided a gain in potency (5a,
5b versus 3a, 3b) and allowed us to identify interesting PTP1B inhibitors.
Compounds 4a, 4e and 4f, which exhibited appreciable dual AR/PTP1B inhibitory
activity, were selected to be further studied for their kinetic behaviour on both target
enzymes and on cultured cells.
2.3. Kinetic Studies
Compounds 4a, 4e and 4f behaved as reversible inhibitors toward both AR and PTP1B
enzymes. In fact, in the case of AR more than 90% of enzyme activity was recovered after
removal of the inhibitor upon extensive dialysis (see Materials and Methods for details).
Similar results were obtained with PTP1B (Supplementary Figure S29).
The evaluation of apparent dissociation constants Ki and K’i for compounds 4a, 4e
and 4f (Table 2 and Supplementary Figures S30–S32) indicated 4e as the most potent
inhibitor toward AR. The characterization of the mechanism of action of the three selected
compounds revealed for 4a a mixed-type inhibition, with a slight preference toward the EIS
complex (K’i approximately 4-fold lower than Ki) (Figure S30). On the other hand, both 4e
(Figure S31) and 4f (Figure S32) resulted to behave essentially as uncompetitive inhibitors
(Ki values at least ten-fold higher concerning the corresponding K’i).









4a 5.0 ± 0.57 1.4 ± 0.022 10.6 ± 1.7 68.9 ± 1.5
4e >8 0.66 ± 0.30 2.2 ± 0.3 >12
4f >30 2.9 ± 0.12 0.9 ± 0.1 2.3 ± 0.1
a Ki and K’i refer to the apparent dissociation constants for the ES and EIS complex, respectively
As far as concerned PTP1B, kinetic analyses revealed that both compounds 4a and
4f behave as mixed-type non-competitive inhibitors. Indeed, in both cases, experimental
points describing the PTP1B catalytic rate in the presence of increasing concentrations of
these compounds were fitted by straight lines intersecting one each other in a point located
in the left quadrant (Supplementary Figures S33 and S35). Moreover, we observed that
both compounds caused an increase of the Km value (Figures S33 and S35B) and a decrease
of Vmax. (Figures S33 and S35C). However, kinetic behaviour of compound 4e appeared
different, as demonstrated by the fact that experimental points described straight lines
intersecting one each other’s in a point located on the Y-axis (Figure S34A). According to
these data, we observed that the Km value increased (Figure S34B), while Vmax did not
change with increasing concentration of compound 4e (Figure S34C); therefore, 4e behaved
as a competitive inhibitor
2.4. AR and PTP1B Docking Experiments
Docking studies of selected AR/PTP1B dual inhibitors 4a, 4e and 4f were carried out
to evaluate their binding mode with both target enzymes and rationalize the observed inhi-
bition mechanisms. In accordance with the kinetic studies that revealed 4a as a mixed AR
inhibitor, whereas 4e and 4f behaved as uncompetitive AR inhibitors, all three compounds
showed consistent docking poses with the AR-idose complex, whereas only 4a revealed
plausible docking poses when docked into the catalytic site of AR.
The shared propionic acid moiety of 4a, 4e and 4f was located outside of the AR
catalytic site, in which L-idose is bound and showed ionic and hydrogen bonding in-
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teractions with Arg217 and Lys221 (Figures 2–4). Hydrogen bonding interactions can
be observed for the carbonyl group in position 4 of the thiazolidinone scaffold with the
backbone of Ala299 and the bridging ether oxygen between the two phenyl rings with
Ser302. The thiocarbonyl group in position 2 was adjacent to Leu301 and pointed towards
the solvent. The 5-benzylidene ring of the compounds formed lipophilic contacts with
Trp219 and Leu301. As shown in our previous study [5], a lipophilic moiety in the meta
position of the 5-benzylidene ring is favourable over a para substitution due to the re-
quired bent that simultaneously allowed the ligands both to form hydrogen bonding with
Arg217 and Lys221 and to fit the lipophilic pocket (Trp20, Val47, Trp79, Phe122) above
the idose-bound competitive binding site. The phenylethoxy moiety in the meta position
of the 5-benzylidene ring (4e, Figure 3) established these interactions, whereas the same
moiety in the para position (4f, Figure 4) was more exposed to the solvent and interacted
only with Phe122 and Leu124 located outside of the lipophilic pocket. The better fit of 4e
compared to 4f is in agreement with the AR inhibitory potency trend (IC50 = 2.3 µM vs.
IC50 = 5.3 µM). The replacement of the phenylethoxy group in the meta position of the
5-benzylidene ring with a phenoxy one (compound 4a) resulted in a detrimental factor
for binding to the lipophilic pocket of the AR-idose complex, which is attributable to the
shorter linker between the two phenyl groups. However, in the case of 4a a better fitting
of the shorter substituent into the AR narrow catalytic centre came out (Figure 5). This
may explain the comparable efficiency of 4a and 4e. On the other hand, 4e and 4f docked
into the catalytic centre revealed unfavorable docking poses where the terminal phenyl
group is evidently solvent exposed, thus confirming the observed uncompetitive mode
of action. A recent analysis from Balestri et al. indicated rational binding modes to the
catalytic centre of AR for different substrates (L-idose, HNE and GSHNE) binding [45]. The
aldehyde moiety of all three substrates shows simultaneous hydrogen bonding to His110
and Tyr48. These interactions were established for 4a neither in our proposed binding
mode nor in the other generated docking poses. The reason for this is the rigidity and
size of 4a compared to AR substrates. The diphenylether moiety of 4a is located slightly
above the catalytic centre, embedded between lipophilic residues Trp20, Val47, Trp79 and
Phe122 (Figure 5). Interestingly, we observed two aromatic ring interactions, where the
thioxothiazolidinone moiety interacted with Trp219 and the 5-benzylidene ring with Trp20.
Furthermore, the thiocarbonyl group in position 2 of the thiazolidinone scaffold established
hydrogen bonding to Ser302 and the carbonyl group in position 4 to the backbone of
Leu300. These observations lead to the conclusion that 4a shows a different binding mode
compared to the AR substrates analysed by Balestri et al. [45] and that direct interaction
with Tyr48 and His110 might not be mandatory for competitive binding to the catalytic site
of AR.
PTP1B kinetic studies showed that 4a and 4f behave as mixed non-competitive in-
hibitors, whereas 4e behaves as a pure competitive inhibitor. Therefore, we performed
docking studies into both the catalytic binding pocket and the previously investigated
allosteric binding pocket of PTP1B [5].
Docking of 4a, 4e and 4f into the catalytic binding site of PTP1B (Figures 6–8) revealed
hydrogen bonding of the propionic acid moiety to Arg221 and the backbones of Phe182,
Ile219 and Gly220. Lipophilic contacts between the 5-benzylidene ring and Tyr46 and
Val49 were observed for all three compounds. The terminal phenyl ring of 4a is embedded
into the lipophilic environment consisting of Val49, Ile219 and Met258, whereas the longer
2-ethoxy linker of compounds 4e and 4f allowed the terminal phenyl ring to reach out
residues Arg24, Arg254 of the adjacent non-catalytic secondary aryl-phosphate binding
site [46]. Additionally, in the same binding site, docking poses of 4e were less consistent
compared to 4a and 4f, revealing binding poses where the terminal phenyl ring is adjacent
to Asp48 and more exposed to the solvent. Therefore, a longer linker on the 5-benzylidene
ring (4e and 4f) appeared to be not advantageous for binding at the catalytic region of
PTP1B, when in meta position, which could explain the lower inhibitory potency of 4e than
4f.





Figure 2. (Top): 3D depiction of the selected pose of 4a bound to the AR-idose complex. Blue surface color: Hydrophilic, 
Yellow surface color: Lipophilic. (Bottom): 2D depiction of protein-ligand interactions of 4a bound to the AR-idose com-
plex. Red circles: hydrogen bond acceptor, Red stars: Anionic interaction, Yellow dotted lines: Lipophilic contacts. 
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Docking of 4a, 4e and 4f into the previously described allosteric binding site of
PTP1B [5] (Figures 9–11) revealed for all three ligands comparable hydrogen bonding
interactions of the propionic acid moiety to Lys103, Arg105 and Arg169 and lipophilic
contacts of the 5-benzylidene ring to Pro210. The shorter linker between the two phenyl
rings of 4a did not allow the carboxyl group to bind to Lys103, Arg105 and Arg169 by
hydrogen bonding and, simultaneously, the terminal phenyl ring to reach the lipophilic
pocket consisting of Pro206 and surrounded by Arg79 and Ser80. The longer ethoxy
linker of 4f enabled both hydrogen bonding and lipophilic contacts at the same time.
This structural feature could explain the higher inhibitory potency of 4f (IC50 = 12.7 µM)
compared to 4a (IC50 = 34.1 µM). Furthermore, the propionic acid in combination with a
meta substitution of the 5-benzylidene ring of 4e made the 5-benzylidene ring more exposed
to the solvent, thus resulting in a lower affinity for this allosteric site of 4e compared to 4a
and 4f. On the whole, these findings were in agreement with the kinetic study and could
further explain the difference in inhibitory potency between 4e and 4a, 4f.
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Figure 5. (Top): 3D depiction of the selected pose of 4a bound to the catalytic center AR. Blue surface color: Hydrophilic,
Yellow surface color: Lipophilic. (Bottom): 2D depiction of protein ligand interactions of 4a bound to the catalytic center of
AR. Red circles: hydrogen bond acceptor, Yellow dotted lines: Lipophilic contacts, Blue donuts: aromatic ring interaction.
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2.5. Ex Vivo Assays
We evaluated the effects of selected compound 4f on HepG2 and C2C12 cells. Cy-
totoxicity of the tested compound was determined using MTT assay. Data reported in
Figure 12 show that 4f was well tolerated by both human HepG2 and murine C2C12 cells,
as demonstrated by the fact that a reduction of cell viability was observed just when cells
(C2C12) were incubated with the highest concentration of compounds (50 µM).
The insulin mimetic/sensitizing activity of compound 4f was evaluated on both
HepG2 and C2C12 cells. Starved HepG2 and C2C12 cells were incubated in the presence of
compound 4f (25 µM) for 90 min and after stimulated or not with insulin (10 nM). Then,
cells extracts were analysed to evaluate phosphorylation levels of the insulin receptor.
Results of the experiments were showed in Figures 13 and 14.
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Figure 7. (Top): 3D depiction of the selected pose of 4e bound to the catalytic center of PTP1B. Blue surface color:
Hydrophilic, Yellow surface color: Lipophilic. (Bottom): 2D depiction of protein-ligand interactions of 4e bound to the
catalytic center of PTP1B. Red circles: hydrogen bond acceptor, Red stars: Anionic interaction, Yellow dotted lines: Lipophilic
contacts.
It is interesting to note that compound 4f showed a different effect on liver and muscle
cells. As far as concerned HepG2 cells, we observed that the treatment with compound 4f
caused a marked reduction of basal phosphorylation levels of IRβ (Figure 13B,C). However,
after stimulation with insulin, IRβ phosphorylation levels increase in both control and
treated cells, although a relatively higher increase has been observed in the latter. In fact, we
calculated that the level of IRβ phosphorylation increases by 39% and 260%, respectively,
in the control and in the cells treated with compound 4f. This finding suggests that the
treatment with compound 4f can make the insulin receptor “more activatable” than that of
untreated cells. At the same time, we observed that treating C2C12 cells with compound
4f did not appreciably affect basal IR phosphorylation levels but significantly improved
insulin activity. According to this hypothesis, we found that IRβ phosphorylation levels
resulted to be significantly higher in treated cells than in those treated with insulin alone
(Figure 14B,C). Taken together, these findings suggest that compound 4f behaves as an
insulin-sensitizing agent in both the liver and muscle cells.
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Figure 12. Viability assay. HepG2 cells (A) and C2C12 cells (B) were incubated in the presence of increasing concentrations 
(µM) of compounds 4f for 48 h. After this time, cells viability was assessed using MTT assay. Data obtained were normal-
ized respect to control test. Data showed in the figure represent the mean ± S.E.M. (n = 4). 
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Figure 12. Viability assay. HepG2 cells (A) and C2C12 cells (B) were incubated in the presence of
increasing concentrations (µM) of compounds 4f for 48 h. After this time, cells viability was assessed
using MTT assay. Data obtained were normalized respect to control test. Data showed in the figure
represent the mean ± S.E.M. (n = 4).




Figure 13. Phosphorylation levels of the insulin receptor in HepG2 cells. Cells were starved for 24 h and then treated 
for 90 min with compound 4f (final concentration 25 µM). After this time, cells were washed with PBS and stimulated 
with insulin (10 nM) for 30 min. Then, cells were washed with cold PBS, lysed and cell extracts analysed by western blot 
to evaluate insulin receptor phosphorylation levels. The intensity of actin bands was used as a loading control. All tests 
were carried out in triplicate (n = 3). (A): western blots. (B,C): quantification of pIRβ/IRβ ratio. 
Figure 13. Phosphorylation levels of the insulin receptor in HepG2 cells. Cells were starved for 24 h and then treated for
90 min with compound 4f (final concentration 25 µM). After this time, cells were washed with PBS and stimulated with
insul (10 nM) for 30 min. Then, cells were washed with cold PBS, lysed and cell xtracts analysed by west rn blot to
evaluate insulin receptor phosphorylation levels. The intensity of actin ba ds was used as a loading control. All tests were
carried out in triplicate (n = 3). (A): western blots. (B,C): quantification of pIRβ/IRβ ratio.
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3. Materials and Methods
3.1. Chemistry
Melting points were recorded on a Kofler t-stage apparatus and are uncorrec ed.
TLC con rols were carried out on pr coated silica gel plates (F 254 M ck). Rf values were
determined by using ppropriate mixtures of diethyl ether/n-hexane as elue t. Combus
tion ana ses (C, H, N), determin d by means of a C. Erba mod. 1106 elem. Analyzer,
were within ±0.4% of t e theoretical values. 1H and 13C-NMR spec ra were recorded on a
Varian 500 MHz spectrometer operating at 499.74 and 125.73 MHz, respectively. Chemical
shifts δ are given i ppm and coupling const nts are ex ressed n Hz. All the pectra were
phased, baseline was corrected where necessar and CDCl3 or DMSO-d6 signals were used
as a r ference for both 1H and 13C spectra. All exch ngeable protons were confirmed by
addition f D2O. Unless stated otherwise, all materials were obtained from commercial
suppliers and used without further purification. 3-(2-Phenylethoxy)benzaldehyde and
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4-(2-phenylethoxy)benzaldehyde were synthesised according to the procedure reported
in ref. 37. Compounds 3d, 4a, 4c, 4d, 4f and 7 are commercially available; however, we
synthesised them according to the procedure described below. The purity of synthetic
compounds was established as ≥ 95% by combustion analysis.
3.1.1. General Procedure for the Synthesis of 5-arylidene-2,4-dioxothiazolidinones 6a–i
A mixture of 2,4-thiazolidinedione (1.17 g, 10 mmol), the appropriate aldehyde
(10 mmol) and piperidine (0.68 g, 8 mmol) in ethanol (70 mL) was refluxed for 24 h. The
crude mixture was poured into H2O acidified with AcOH (pH 3–4) to give a crude solid
which was recrystallized from methanol to provide the corresponding pure 5-arylidene-2,4-
thiazolidinedione 6. Chemical-physical and spectroscopic data of compounds 6a–i were
reported in Refs. [26,37].
3.1.2. General Procedure for the Synthesis of 3-(5-arylidene-2,4-dioxothiazolidin-3-yl)
propanoic Acids 3a–f
A mixture of 5-arylidene-2,4-thiazolidinedione 6 (1.68 mmol), 3-chloropropanoic acid
(0.365 g, 3.36 mmol) and potassium carbonate (0.93 g, 6.73 mmol) in anhydrous acetone
(40 mL) was refluxed for 24 h. The solvent was evaporated under reduced pressure. The
solid residue was poured into H2O, acidified with HCl 6M (pH 3) and stirred until CO2
disappearance. The solid was filtered off, washed with H2O and recrystallized from
methanol to provide pure compounds 3.
3-{(5Z)-[2,4-Dioxo-5-(3-phenoxyphenyl)methylidene]thiazolidin-3-yl}propanoic acid (3a). Yield
66% (409.6 mg); m.p. 177–180 ◦C; 1H-NMR (DMSO-d6): δ 2.59 (t J = 7.5 Hz, 2H, CH2COOH);
3.84 (t J = 7.5 Hz, 2H, NCH2); 7.09 (m, 2H, arom); 7.13 (m, 1H, arom); 7.19–7.23 (m, 2H,
arom); 7.37 (m, 1H arom); 7.44 (m, 2H, arom), 7.54 (m, 1H, arom); 7.90 (s, 1H, methylidene);
12.45 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 32.0 (CH2), 38.0 (CH2), 119.5 (CH), 119.9
(CH), 120.8 (C), 122.8 (C), 124.8 (CH), 125.4 (CH), 130.8 (CH), 131.6 (CH), 132.7 (CH), 135.4
(CH), 156.3 (C), 158.2 (C), 165.8 (C), 167.4 (C), 172.4 (C). Anal. (C19H15NO5S) calcd: C 61.78;
H 4.09; N 3.97; found: 61.92; H 4.03; N 3.99.
3-{(5Z)-[2,4-Dioxo-5-(4-phenoxyphenyl)methylidene]thiazolidin-3-yl}propanoic acid (3b). Yield
60% (372.3 mg); m.p. 198–202 ◦C; 1H-NMR (DMSO-d6): δ 2.60 (t J = 7.5 Hz, 2H, CH2COOH);
3.86 (t J = 7.5 Hz, 2H, NCH2); 7.11 (m, 4H, arom); 7.24 (m, 1H, arom); 7.45 (m, 2H, arom);
7.64 (m, 2H arom); 7.90 (s, 1H, methylidene); 12.45 (s, 1H, COOH). 13C-NMR (DMSO-d6):
δ 32.1 (CH2), 38.0 (CH2), 118.9 (CH), 120.1 (CH), 120.4 (C), 125.2 (CH), 128.2 (C), 130.9
(CH), 132.9 (CH), 133.0 (CH), 155.7 (C), 159.6 (C), 166.0 (C), 167.6 (C), 172.4 (C). Anal.
(C19H15NO5S) calcd: C 61.78; H 4.09; N 3.97; found: C 61.97; H 3.98; N 4.01.
3-{(5Z)-[5-(3-Benzyloxyphenyl)methylidene]-2,4-dioxothiazolidin-3-yl}propanoic acid (3c). Yield
25% (161.0 mg); m.p. 142–145 ◦C; 1H-NMR (DMSO-d6): δ 2.60 (t J = 7.5 Hz, 2H, CH2COOH);
3.86 (t J = 7.5 Hz, 2H, NCH2); 5.17 (s, 2H, OCH2); 7.14–7.20 (m, 2H, arom); 7.24 (s, 1H, arom);
7.34 (m, 1H, arom); 7.40 (m, 2H arom); 7.44–7.48 (m, 3H, arom); 7.88 (s, 1H, methylidene);
12.45 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 32.0 (CH2), 38.0 (CH2), 70.0 (CH2), 116.7
(CH), 118.0 (C), 122.3 (C), 122.9 (CH), 128.3 (CH), 128.5 (CH), 129.1 (CH), 131.1 (CH), 133.3
(CH), 134.9 (CH), 137.2 (C), 159.3 (C), 165.9 (C), 167.6 (C), 172.4 (C). Anal. (C20H17NO5S)
calcd: C 62.65; H 4.47; N 3.65; found: C 62.83; H 4.51; N 3.48.
3-{(5Z)-[5-(4-Benzyloxyphenyl)methylidene]-2,4-dioxothiazolidin-3-yl}propanoic acid (3d). Yield
61% (392.9 mg); m.p. 195–199 ◦C; 1H-NMR (DMSO-d6): δ 2.58 (t J = 7.5 Hz, 2H, CH2COOH);
3.85 (t J = 7.5 Hz, 2H, NCH2); 5.19 (s, 2H, OCH2); 7.18 (m, 2H, arom); 7.34 (m, 1H, arom);
7.40 (m, 2H, arom); 7.46 (m, 2H arom); 7.59 (m, 2H, arom); 7.88 (s, 1H, methylidene); 12.42
(s, 1H, COOH). 13C-NMR (DMSO-d6): δ 32.2 (CH2), 38.0 (CH2), 70.1 (CH2), 116.3 (CH),
118.7 (C), 126.2 (C), 128.4 (CH), 128.6 (CH), 129.1 (CH), 132.8 (CH), 133.4 (CH), 134.9 (CH),
137.0 (C), 160.8 (C), 166.1 (C), 167.7 (C), 172.6 (C). Anal. (C20H17NO5S) calcd: C 62.65; H
4.47; N 3.65; found: C 62.78; H 4.56; N 3.55.
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3-[(5Z)-2,4-Dioxo-{5-[3-(2-phenylethoxy)phenyl]methylidene}thiazolidin-3-yl]propanoic acid (3e).
Yield 81% (540.8 mg); m.p. 130–133 ◦C; 1H-NMR (DMSO-d6): δ 2.60 (t J = 7.5 Hz, 2H,
CH2COOH); 3.06 (t J = 6.8 Hz, 2H, CH2Ph); 3.86 (t J = 7.5 Hz, 2H, NCH2); 4.25 (t J = 6.8 Hz,
2H, OCH2); 7.07 (m, 1H, arom); 7.16–7.24 (m, 3H, arom); 7.3–7.35 (m, 4H, arom); 7.44 (m,
1H arom); 7.89 (s, 1H, methylidene); 12.45 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 32.0
(CH2), 35.4 (CH2), 38.0 (CH2), 68.9 (CH2), 116.6 (CH), 117.7 (C), 122.2 (C), 122.4 (CH), 126.9
(CH), 128.9 (CH), 129.5 (CH), 131.1 (CH), 133.4 (CH), 134.9 (CH), 138.8 (C), 159.4 (C), 165.9
(C), 167.6 (C), 172.4 (C). Anal. (C21H19NO5S) calcd: C 63.46; H 4.82; N 3.52; found: C 63.66;
H 4.89; N 3.48
3-[(5Z)-2,4-Dioxo-{5-[4-(2-phenylethoxy)phenyl]methylidene}thiazolidin-3-yl]propanoic acid (3f).
Yield 73% (487.4 mg); m.p. 160–163 ◦C; 1H-NMR (DMSO-d6): δ 2.59 (t J = 7.2 Hz, 2H,
CH2COOH); 3.06 (t J = 6.9 Hz, 2H, CH2Ph); 3.85 (t J = 7.2 Hz, 2H, NCH2); 4.28 (t J = 6.9 Hz,
2H, OCH2); 7.11 (m, 2H, arom); 7.23 (m, 1H, arom); 7.30–7.34 (m, 4H, arom); 7.57 (m, 2H,
arom); 7.87 (s, 1H, methylidene); 12.44 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 32.1 (CH2),
35.3 (CH2), 37.9 (CH2), 69.0 (CH2), 116.0 (CH), 118.5 (C), 126.0 (C), 126.9 (CH), 128.9 (CH),
129.5 (CH), 132.8 (CH), 133.5 (CH), 138.6 (C), 160.9 (C), 166.1 (C), 167.7 (C), 172.4 (C). Anal.
(C21H19NO5S) calcd: C 63.46; H 4.82; N 3.52; found: C 63.55; H 4.80; N 3.54.
3.1.3. General Procedure for the Synthesis of 3-(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)
propanoic Acids 4a–f
To a solution of β-alanine (1 g, 12.49 mmol) and NaOH (0.5 g, 12.49 mmol) in H2O
(35 mL) CS2 (2.25 mL, 37.46 mmol) was added dropwise, in such a manner that the temper-
ature of the reaction did not exceed 25 ◦C and the mixture was stirred at room temperature
for 24 h. A solution of sodium bromoacetate, obtained by solubilizing bromoacetic acid
(1.73 g, 12.49 mmol) and NaOH (0.5 g, 12.49 mmol) in H2O (45 mL), was added and the
mixture was stirred at room temperature for a further 24 h. The mixture was acidified
with HCl 6M until pH 3–4 and refluxed for 24 h. The mixture was then cooled and poured
into H2O, providing a pale yellow precipitate. Then, if necessary, pH was adjusted again
to 3–4 by the addition of HCl 6M and the solid was filtered off. The aqueous solution
was extracted with ethyl acetate; the organic phase was washed with H2O, dried with
anhydrous Na2SO4 and evaporated under reduced pressure, providing a further amount of
3-(4-oxo-2-thioxothiazolidin-3-yl)propanoic acid (7). The solid residue and the precipitate
were collected and washed with ethyl ether to give pure compound 7. Yield 35% (897.2 mg);
mp 159–162 ◦C; 1H-NMR (CDCl3): δ 2.77 (t J = 6 Hz, 2H, CH2COOH), 4.01 (s, 2H, 5-CH2)
4.31 (t J = 6 Hz, 2H, NCH2). Anal. (C6H7NO3S2) calcd: C 35.11; H 3.44; N 6.82; found: C
34.96, H 3.34, N 6.92.
A mixture of 3-(4-oxo-2-thioxothiazolidin-3-yl)propanoic acid (7) (0.25 g, 1.22 mmol)
glacial acetic acid (10 mL), sodium acetate (1.24 g, 9.13 mmol) and the appropriate alde-
hyde (1.22 mmol) was refluxed for 3–4 h. The mixture was cooled and poured into H2O,
providing a precipitate which was filtered off, washed with H2O and recrystallized from
methanol to give pure 3-[(5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)]propanoic acids 4.
3-{(5Z)[4-Oxo-5-(3-phenoxyphenyl)methylidene-2-thioxothiazolidin-3-yl]}propanoic acid (4a). Yield
46% (216.3 mg); m.p. 174–175 ◦C; 1H-NMR (DMSO-d6): δ 2.57 (t J = 7.5 Hz, 2H, CH2COOH);
4.15 (t J = 7.5 Hz, 2H, NCH2); 7.01–7.03 (m, 3H, arom); 7.08 (m, 1H, arom); 7.18 (m, 1H,
arom); 7.27 (m, 1H, arom); 7.38–7.41 (m, 2H, arom); 7.49 (m, 1H, arom); 7.63 (s, 1H, CH
methylidene). 13C-NMR (DMSO-d6): δ 31.9 (CH2), 41.1 (NCH2), 120.0 (CH), 120.4 (CH),
120.5 (C), 121.8 (CH), 124.3 (CH), 125.5 (CH), 126.5 (CH), 131.4 (CH), 132.4 (CH), 133.3 (CH),
135.7 (C), 156.7 (C), 158.8 (C), 167.7 (C), 173.1 (C), 194.0 (C). Anal. (C19H15NO4S2) calcd: C
59.20; H 3.92; N 3.63; found: C 59.06; H 4.01; N 3.60.
3-{(5Z)[4-Oxo-5-(4-phenoxyphenyl)methylidene-2-thioxothiazolidin-3-yl]}propanoic acid (4b). Yield
46% (216.3 mg); m.p. 218–219 ◦C; 1H-NMR (DMSO-d6): δ 2.62 (t J = 7.5 Hz, 2H, CH2COOH);
4.22 (t J = 7.5 Hz, 2H, NCH2); 7.11 (m, 3H, arom); 7.24 (m, 2H, arom); 7.45 (m, 2H, arom);
7.64 (m, 2H, arom); 7.76 (s, 1H, CH methylidene). 13C-NMR (DMSO-d6): δ 31.7 (CH2), 40.8
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(NCH2), 119.2 (CH), 120.8 (CH), 121.4 (C), 125.7 (CH), 128.4 (CH), 131.2 (C), 133.4 (CH),
133.9 (CH), 155.8 (C), 160.3 (C), 167.6 (C), 172.7 (C), 194.0 (C). Anal. (C19H15NO4S2) calcd:
C 59.20; H 3.92; N 3.63; found: C 59.25; H 4.00; N 3.57.
3-{(5Z)-5-[(3-Benzyloxyphenyl)methylidene]-4-oxo-2-thioxothiazolidin-3-yl}propanoic acid (4c).
Yield 62% (302.2 mg); m.p. 207–209 ◦C; 1H-NMR (DMSO-d6): δ 2.62 (t J = 7.5 Hz, 2H,
CH2COOH); 4.21 (t J = 7.5 Hz, 2H, NCH2); 5.16 (s, 2H, OCH2); 7.15–7.19 (m, 3H, arom); 7.33
(m, 1H, arom); 7.39 (m, 2H, arom); 7.44–7.47 (m, 3H, arom); 7.73 (s, 1H, CH methylidene).
13C-NMR (DMSO-d6): δ 31.8 (CH2), 41.0 (CH2), 70.4 (CH2), 117.3 (CH), 119.0 (C), 123.8
(CH), 124.0 (C), 128.7 (CH), 129.1 (CH), 129.6 (CH), 131.8 (CH), 133.9 (CH), 135.2 (CH),
137.5 (C), 159.7 (C), 167.7 (C), 172.9 (C), 194.2 (C). Anal. (C20H17NO4S2) calcd: C 60.13; H
4.29; N 3.51; found: C 59.97; H 4.18; N 3.61.
3-{(5Z)-5-[(4-Benzyloxyphenyl)methylidene]-4-oxo-2-thioxothiazolidin-3-yl}propanoic acid (4d).
Yield 49% (238.8 mg); m.p. 170–173 ◦C; 1H-NMR (DMSO-d6): δ 2.61 (t J = 7.5 Hz, 2H,
CH2COOH); 4.21 (t J = 7.5 Hz, 2H, NCH2); 5.20 (s, 2H, OCH2); 7.19 (m, 2H, arom); 7.34–7.48
(m, 5H, arom); 7.62 (m, 2H, arom); 7.78 (s, 1H, CH methylidene). 13C-NMR (DMSO-d6): δ
31.5 (CH2), 40.6 (CH2), 70.2 (CH2), 116.5 (CH), 119.8 (C), 126.3 (C), 128.4 (CH), 128.6 (CH),
129.1 (CH), 133.5 (CH), 133.7 (CH), 137.0 (C), 161.2 (C), 167.3 (C), 172.4 (C), 193.7 (C). Anal.
(C20H17NO4S2) calcd: C 60.13; H 4.29; N 3.51; found: C 60.17; H 4.35; N 3.45.
3-[(5Z)-4-Oxo-{5-[3-(2-phenylethoxy)phenyl]methylidene}-2-thioxothiazolidin-3-yl]propanoic acid
(4e). Yield 26% (131.2 mg); m.p. 136–138 ◦C; 1H-NMR (DMSO-d6): δ 2.63 (t J = 7.5 Hz, 2H,
CH2COOH); 3.05 (t J= 6.8 Hz, 2H, CH2Ph); 4.20–4.26 (m, 4H, NCH2 and OCH2); 7.08 (m,
1H, arom); 7.15–7.18 (m, 2H, arom); 7.22 (m, 1H, arom); 7.29–7.34 (m, 4H, arom); 7.45 (m,
1H, arom); 7.76 (s, 1H, CH methylidene). 13C-NMR (DMSO-d6): δ 31.5 (CH2), 35.5 (CH2),
40.7 (CH2), 69.1 (CH2), 117.0 (CH), 118.3 (C), 123.2 (C), 123.4 (CH), 127.1 (CH), 129.1 (CH),
129.7 (CH), 131.4 (CH), 133.7 (CH), 135.0 (CH), 138.9 (C), 159.6 (C), 167.3 (C), 172.5 (C),
193.9 (C). Anal. (C21H19NO4S2) calcd: C 61.00; H 4.63; N 3.39; found: C 61.18; H 4.74; N
3.25.
3-[(5Z)-4-Oxo-{5-[4-(2-phenylethoxy)phenyl]methylidene}-2-thioxothiazolidin-3-yl]propanoic acid
(4f). Yield 26% (131.2 mg); m.p. 171–174 ◦C; 1H-NMR (DMSO-d6): δ 2.63 (t J = 7.5 Hz, 2H,
CH2COOH); 3.05 (t J= 6.8 Hz, 2H, CH2Ph); 4.23 (t J = 7.5 Hz, 2H, NCH2); 4.29 (t J = 6.8 Hz,
2H, OCH2); 7.12 (m, 2H, arom); 7.23 (m, 1H, arom); 7.30–7.34 (m, 4H, arom); 7.59 (m, 2H,
arom); 7.77 (s, 1H, CH methylidene); 12.51 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 31.4
(CH2), 35.3 (CH2), 40.6 (CH2), 69.1 (CH2), 116.2 (CH), 119.6 (C), 126.1 (C), 126.9 (CH), 128.9
(CH), 129.5 (CH), 133.5 (CH), 133.8 (CH), 138.6 (C), 161.3 (C), 167.3 (C), 172.3 (C), 193.7 (C).
Anal. (C21H19NO4S2) calcd: C 61.00; H 4.63; N 3.39; found: C 60.92; H 4.58; N 3.51.
3.1.4. General Procedure for the Synthesis of 4-(5-arylidene-2,4-dioxothiazolidin-3-yl)-2
-butenoic Acids 5a–e
A mixture of 5-arylidene-2,4-thiazolidinedione 6 (2.5 mmol), methyl 4-bromocrotonate
(0.9 g, 5 mmol) and potassium carbonate (0.69 g, 5 mmol) in anhydrous acetone (50 mL)
was refluxed for 24 h. After cooling, the inorganic salts were filtered off and the solvent
was evaporated under reduced pressure. The solid residue was washed with H2O and
recrystallized from ethanol providing pure 4-(5-arylidene-2,4-dioxothiazolidin-3-yl)-2-
butenoic acid methyl esters.
A mixture of the corresponding methyl ester (2.1 mmol), glacial acetic acid (8.5 mL)
and HCl 12M (2.1 mL) was refluxed for 2 h. The reaction mixture was poured into H2O and
the precipitate was filtered off. The crude solid was washed with H2O and recrystallized
from methanol to provide pure 2-butenoic acids 5. Chemical-physical and spectroscopic
data of compounds 5a–c were reported in [26].
4-{(5Z)-[5-(1-Naphtylmethylidene)-2,4-dioxothiazolidin-3-yl]}-2-butenoic acid (5d). Yield 26%
(220.6 mg); m.p. 170–172 ◦C; 1H-NMR (DMSO-d6): δ 4.47 (d J = 5.0 Hz, 2H, NCH2); 5.90
(d J = 15.5 Hz, 1H, CHCOOH); 6.83 (dt J = 15.5 and 5.0 Hz, 1H, CHCH2); 7.62–7.72 (m,
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4H, arom); 8.03–8.15 (m, 3H, arom); 8.57 (s, 1H, CH methylidene), 12.52 (s, 1H, COOH).
13C-NMR (DMSO-d6): δ 42.4 (CH2), 123.7 (CH), 124.1 (CH), 125.6 (CH), 126.2 (CH), 127.1
(CH), 127.5 (CH), 128.1 (CH), 129.5 (CH), 130.7 (CH), 130.8 (C), 131.5 (C), 133.8 (C), 141.2
(CH), 165.4 (C), 167.0 (C), 167.9 (C), 171.3 (C). Anal. (C18H13NO4S) calcd: C 63.71; H 3.86;
N 4.13; found: C 63.59; H 3.76; N 4.22.
4-{(5Z)-[5-(2-Naphtylmethylidene)-2,4-dioxothiazolidin-3-yl]}-2-butenoic acid (5e). Yield 70%
(593.9 mg); m.p. 235–238 ◦C; 1H-NMR (DMSO-d6): δ 4.45 (d J = 5.0 Hz, 2H, NCH2); 5.87 (d
J = 16.0 Hz, 1H, CHCOOH); 6.81 (dt J = 16.0 and 5.0 Hz, 1H, CHCH2); 7.59–7.65 (m, 2H,
arom); 7.71 (m, 1H, arom); 7.97 (m, 1H, arom); 8.04–8.08 (m, 3H, arom); 8.22 (s, 1H, CH
methylidene); 12.49 (s, 1H, COOH). 13C-NMR (DMSO-d6): δ 42.4 (CH2), 122.1 (C), 123.6
(CH), 126.5 (CH), 127.8 (CH), 128.3 (CH), 128.7 (CH), 129.4 (CH), 129.6 (CH), 131.1 (CH),
131.8 (CH), 133.3 (C), 133.7 (C), 133.9 (C), 141.2 (CH), 165.8 (C), 167.0 (C), 167.7 (C). Anal.
(C18H13NO4S) calcd: C 63.71; H 3.86; N 4.133; found: C 63.78; H 3.94; N 4.07.
3.2. Enzymatic Assays
3.2.1. AR Enzymatic Assay, Expression and Purification
The human recombinant AR was expressed in BL21(DE3)pLysS E. coli cells and
purified to electrophoretic homogeneity as previously described [47]. The purified enzyme
(specific activity 5.0 U/mg) was stored at −80 ◦C in 10 mM sodium phosphate buffer pH
7.0 containing 2 mM dithiothreitol and 30% (w/v) glycerol. AR activity was determined at
37 ◦C as previously described [48] evaluating the decrease in absorbance at 340 nm linked
to NADPH oxidation. The standard assay mixture contained 0.25 M sodium phosphate
buffer pH 6.8, 0.18 mM NADPH, 2.4 M ammonium sulfate, 0.5 mM EDTA and 4.7 mM
GAL. One unit of enzyme activity is the amount that catalyzes the conversion of 1 µmol of
substrate/min in the above assay conditions.
3.2.2. Inhibition Studies on AR
The determination of IC50 (concentration of compound required to determine a 50%
inhibition of enzyme activity) values was performed in the above described assay condi-
tions using 2 mM L-idose as substrate. All compounds tested as aldose reductase inhibitors
were dissolved in DMSO and added to the assay mixture containing 8 mU of purified AR.
The reaction was started by addition of the substrate. The DMSO concentration in all the
assays was kept constant at 0.5% (v/v) in order to avoid effects on AR activity [49].
The IC50 values were determined by nonlinear regression analysis using Prism Graph-









)slope + Min (1)
In the equation, vi/v0, represents the ratio between the activity measured in the
presence of the inhibitor and the activity measured in the absence of inhibitor; Max and Min
represent the expected maximal and minimal value of the activity and were fixed at 1 and
zero, respectively. Slope, which describes the steepness of curve in the transition region,
was fixed at −1. For each compound, at least five different concentrations of inhibitor in
the triplicate assay were analyzed.
The kinetic analysis of compounds 4a, 4e and 4f was performed by measuring reaction
rates with different L-idose concentrations s (S) in the absence and in the presence of
different inhibitors concentrations. Data were analyzed by Linewever-Burk plots. The
apparent dissociation constants Ki’ (for the ESI complex) and Ki (for the EI complex) were
determined from secondary plots of 1/Vmax and KM/Vmax as a function of the inhibitor
concentration, respectively.
In order to evaluate the reversibility of the inhibitory action, 8 mU of purified AR were
assayed in the presence of 5 µM of compounds 4a, 4e and 4f. In these conditions less than
15% of the enzyme activity was measured in the presence of 2 mM L-idose as substrate. The
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mixture was then extensively dialysed on Amicon ultrafiltration membrane (cut off 10 KDa)
against 10 mM sodium phosphate buffer, pH 7.0. After dialysis, the enzyme activity was
again measured as above and compared to that of a mixture in the absence of inhibitor and
treated in the same conditions.
3.2.3. Enzymatic Assays with PTP1B
PTP1B activity was determined as follow. An aliquot of human recombinant PTP1B
was diluted in the assay buffer containing 0.075 M β-β-dimethylglutarate pH 7.0, 1 mM
EDTA, 0.1 mM DTT and p-nitrophenyl phosphate (pNPP) as substrate. After an appropriate
interval time, the reaction was stopped diluting assay solution with 2 mL of KOH 0.1 M.
The amount of p-nitrophenol released was determined measuring the absorbance of the
solution at 400 nm using a spectrophotometer and a 1-cm optical pathlength (εmM of
p-nitrophenol is 18).
The IC50 value was determined measuring the pNPP hydrolysis rate in the presence
of increasing inhibitor concentration. For each inhibitor, 15–16 different concentrations
were used. All tests were carried out in triplicate and data obtained were normalized
respect to control sample. Experimental points were fitted using Equation (1), shows in the
Section 3.2.2.
3.2.4. Reversibility Assay (Dilution Test) with PTP1B
An aliquot of the enzyme was incubated for 60 min at 37 ◦C in the presence of saturat-
ing amount of PTP1B inhibitor. After this time, an aliquot of the enzyme was withdrawn
and diluted 400 folds in the assay buffer containing 2.5 mM of pNPP. After 15 min, the
reaction was stopped by adding 1 mL of KOH 0.2 M. The amount of pNP released was
calculating measuring the absorbance at 400 nm of solutions using a spectrophotometer.
Data obtained were normalized respect to control tests, which was carried out diluting
the enzyme with DMSO, the solvent used to dissolve all compounds. Data reported in the
figure represent the mean value +/− S.E.M. (n = 3).
3.2.5. Evaluation of Action Mechanism of Inhibitors
Kinetic analyses were carried out to dissect action mechanism of compound 4e and
4f. Briefly, the main kinetic parameters, Km and Vmax, were calculated measuring the
initial hydrolysis rate of PTP1B in the presence of increasing pNPP concentration (seven
different concentrations in the 0.5–25 mM range). All assays were carried out in duplicate.
Data obtained were fitted using the Michaelis-Menten equation. To evaluate the action
mechanism of inhibitors, we studied the dependence of Km and Vmax from inhibitors
concentration, using three different inhibitor concentrations, at least. Data obtained were
then analysed by double reciprocal plot (Lineweaver-Burk plot).
3.3. Ex Vivo Assay
3.3.1. Cell Cultures
Human liver cells (HepG2) and murine myoblasts (C2C12) were purchased by Sigma-
Aldrich, which obtained them from the European Collection of Authenticated Cell Cultures
(ECACC). HepG2 and C2C12 cells were grown in Dulbecco’s Modified Eagle’s medium
(DMEM) supplemented with 10% foetal bovine serum (FBS), 2 mM glutamine, 100 IU/mL
penicillin, 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA), in a humidified
atmosphere and with 5% CO2 at 37 ◦C. Differentiation of C2C12 was induced incubating
murine myoblasts in DMEM supplemented with 2% horse serum. C2C12 cells were plated
and grown until they reach 70% confluence. Then, cells were incubated in the presence
of 2% horse serum for 96 h. Every 48 h, the medium was replaced with fresh medium.
After 96 h, the degree of differentiation was evaluated analysing cells with a contrast phase
microscope.
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3.3.2. Cell Viability Assay
HepG2 and C2C12 cells were incubated in the presence of increasing concentrations
of compounds 4e and 4f for 48 h at 37 ◦C. After this time, cells were washed with PBS
and then incubated for 1 h with 0.5 mg/mL of MTT dissolved in complete medium. Then
cells were washed and lysed with 300 µL of DMSO. The absorbance of solutions were
evaluated using a microplate readers at 595 nm. All data were normalized respect to control
experiment. Data showed in the figures represent the mean values ± S.E.M. (n = 4).
3.3.3. Evaluation of Insulin Mimetic/Sensibilizing Activity of Inhibitors
HepG2 and differentiated C2C12 cells were starved for 24 h and then incubated in
the presence of compound 4f (25 µM, final concentration) for 90 min. After this time, cells
were washed with PBS and then stimulated or not with 10 nM insulin for 30 min. Then,
cells were lysed and cellular proteins separated on a 12% SDS-PAGE. After electrophoresis,
cellular proteins were transferred on a PVDF membrane by western blot technique and
then probed against antibodies able to specifically recognize insulin receptor (I2033 Sigma
Aldrich) or phosphorylated form of IR (MABS65, Sigma-Aldrich). Sample loading was
evaluated probing PVDF membrane with anti-actin antibodies (ABT1485 Sigma Aldrich).
3.4. Molecular Docking
Crystal structure selection and preparation for PTP1B (PDB 1Q6T [50]) and the AR-
idose complex (based on PDB 3V36 [51]) was carried out as described in our previous
study [5]. Docking studies were performed into the catalytic site of PTP1B and AR, the
AR-idose complex and our previously described allosteric binding pocket of PTP1B [5]
with GOLD (version 5.2) [52], generating 25 docking poses per ligand with standard
settings using the scoring function CHEMPLP. In order to select a docking pose, the 25
docking poses were clustered based on LigandScouts [53,54] pharmacophore RDF-Code
(radial distribution function) similarity. Finally, all selected docking poses have been energy
minimized in Ligand Scout with the MMFF94 Force Field [55]. 3D protein ligand depictions
were rendered with MOE (version 2019) [56] and 3D pharmacophores were developed
using Ligand Scout.
Virtual Screening
Shape-based virtual screening was performed with ROCS (OpenEye, Scientific Soft-
ware, Santa Fe, NM, USA) [57] using default options. Docking of virtual screening hits
was carried out with the software package GOLD (version 5.2) [52] into the catalytic cen-
tre of PTP1B (PDB 1Q6T [50]), generating 10 docking poses per ligand with standard
settings as described above. The hit compound 3-{[5-(4-benzyloxyphenyl)methylidene]-
2,4-dioxothiazolidin-3-yl}propanoic acid was identified by using the co-crystallized ligand
(4-bromo-3-(carboxymethoxy)-5-[3-(cyclohexylamino)phenyl]thiophene-2-carboxylic acid)
from the PTP1B crystal structure 2QBS [58] as the template for the ROCS screening. The
compound was found screening the vendor space of Enamine HTS Collection (as of
06/2014).
4. Conclusions
The appreciable in vitro activity of compounds 4a, 4e and 4f as well as 5a and 5d
as dual AR/PTP1B inhibitors provided further insights into the possibility to develop
4-thiazolidinone derivatives as new potential multitarget antidiabetic candidates. Taking
into account that the partial inhibition of selected targets, in particular enzymes, may
be therapeutically more effective than the total control of a single target [2,3], these dual
inhibitors, along with previous analogues 1e and 2e, appear to be promising as lead
compounds, whose inhibitory activity towards both target enzymes might be further im-
proved. In particular, compound 4f exhibited the most interesting profile, with balanced
AR/PTP1B inhibitory effectiveness at low micromolar concentrations, along with promis-
ing insulin-sensitizing activity in cultured cells. The IC50 values of 4f against both human
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PTP1B and human AR resulted in being in the low micromolar range, whereas those of
the corresponding acetic acid analogue of series 2 differ of two orders of magnitude [5].
Therefore, although the elongation of the carboxylic chain on N-3 of the thiazolidinone
scaffold produced a decrease in AR inhibitory effectiveness, this structural feature was
responsible for a gain in potency against PTP1B, thus providing a more balanced inhibition
profile towards the two target enzymes.
The SARs that emerged from our enzyme inhibition data, also considering our previous
findings, highlighted that the AR inhibitory potency of the investigated 4-thiazolidinones
is mainly influenced by the nature of the substituents in positions 2 and 3 of the hete-
rocyclic scaffold and only in a lesser extent by the nature of the 5-arylidene moiety. On
the other hand, this latter structural portion appeared to be critical to achieving good
PTP1B inhibition, considering that a more extended 5-arylidene portion, in particular
a (2-phenylethoxy)benzylidene moiety, showed to be more beneficial. In addition, a
thiocarbonyl group in position 2 of the thiazolidinone scaffold generally proved to be
advantageous to achieve gain in potency towards both target enzymes. The elongation
of the carboxylic chain on N-3 in several cases improved inhibitory effectiveness towards
PTP1B; propanoic acid derivatives 4a, 4e and 4f as well as 2-butenoic acid derivatives 5a
and 5d exhibited good capability to inhibit both human PTP1B and AR. The data reported
here allowed us to extend the SARs of this class of DMLs, which were rationalized by
in silico docking experiments into both target enzymes. Therefore, these findings can be
of interest for the design of new 4-thiazolidinone derivatives endowed with improved
pharmacological profiles.
Supplementary Materials: The supplementary materials are available online.
Author Contributions: Conceptualization, R.O., R.M. (Rosanna Maccari), A.D.C., T.N.N., A.N. and
G.W.; Synthetic methodologies R.O., R.M. (Rosanna Maccari) and I.A.; Validation & Investigation,
R.O., R.M. (Rosanna Maccari), T.N.N., A.N., G.W., M.C. and R.M. (Roberta Moschini); Data Curation,
I.A., M.C., M.G., I.N., T.N.N. and A.N.; Writing-review editing R.O., R.M. (Rosanna Maccari), A.D.C.,
P.P., T.N.N. and G.W. All authors have read and agreed to the published version of the manuscript.
Funding: The APC was funded by MDPI.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available in this article and relative
supplementary material.
Acknowledgments: This work was supported by University of Messina, University of Florence and
University of Pisa.
Conflicts of Interest: The authors declare no conflict of interest.
Sample Availability: Samples of the compounds are not available from the authors.
References
1. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. J. Med. Chem. 2005, 48, 6523–6543.
[CrossRef]
2. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. Trends
Pharmacol. Sci. 2005, 26, 178–182. [CrossRef]
3. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682–690. [CrossRef]
4. Proschak, E.; Stark, H.; Merk, D. Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds.
J. Med. Chem. 2019, 62, 420–444. [CrossRef]
5. Maccari, R.; Del Corso, A.; Paoli, P.; Adornato, I.; Lori, G.; Balestri, F.; Cappiello, M.; Naß, A.; Wolber, G.; Ottanà, R. An
investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the
search for potential agents for the treatment of type 2 diabetes mellitus and its complications. Bioorganic Med. Chem. Lett. 2018, 28,
3712–3720. [CrossRef] [PubMed]
6. Cho, N.H.; Shaw, J.E.; Karuranga, S.; Huang, Y.; Fernandes, J.D.R.; Ohlrogge, A.; Malanda, B. IDF Diabetes Atlas: Global estimates
of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018, 138, 271–281. [CrossRef] [PubMed]
Molecules 2021, 26, 330 30 of 32
7. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova,
K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the
International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [CrossRef] [PubMed]
8. Gattrell, W.; Johnstone, C.; Patel, S.; Smith, C.S.; Scheel, A.; Schindler, M. Designed multiple ligands in metabolic disease research:
From concept to platform. Drug Discov. Today 2013, 18, 692–696. [CrossRef] [PubMed]
9. Dowarah, J.; Singh, V.P. Anti-diabetic drugs recent approaches and advancements. Bioorganic Med. Chem. 2020, 28, 115263.
[CrossRef] [PubMed]
10. Srivastava, S.K.; Ramana, K.V.; Bhatnagar, A. Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent
Potential for Therapeutic Options. Endocr. Rev. 2005, 26, 380–392. [CrossRef]
11. Maccari, R.; Ottanà, R. Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases:
New Insights and Future Directions. J. Med. Chem. 2015, 58, 2047–2067. [CrossRef] [PubMed]
12. Ramana, K.V.; Srivastava, S.K. Aldose reductase: A novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell
Biol. 2010, 42, 17–20. [CrossRef] [PubMed]
13. Frohnert, B.I.; Long, E.K.; Hahn, W.S.; Bernlohr, D.A. Glutathionylated Lipid Aldehydes Are Products of Adipocyte Oxidative
Stress and Activators of Macrophage Inflammation. Diabetes 2013, 63, 89–100. [CrossRef] [PubMed]
14. Di Paola, R.; Frittitta, L.; Miscio, G.; Bozzali, M.; Baratta, R.; Centra, M.; Spampinato, D.; Santagati, M.G.; Ercolino, T.; Cisternino,
C.; et al. A Variation in 3′ UTR of hPTP1B Increases Specific Gene Expression and Associates with Insulin Resistance. Am. J. Hum.
Genet. 2002, 70, 806–812. [CrossRef] [PubMed]
15. Cheng, A.; Uetani, N.; Simoncic, P.D.; Chaubey, V.P.; Lee-Loy, A.; McGlade, C.J.; Kennedy, B.P.; Tremblay, M.L. Attenuation of
leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2002, 2, 497–503. [CrossRef]
16. Zhang, Z.-Y.; Dodd, G.T.; Tiganis, T. Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling. Trends
Pharmacol. Sci. 2015, 36, 661–674. [CrossRef]
17. Zabolotny, J.M.; Kim, Y.-B.; Welsh, L.A.; Kershaw, E.E.; Neel, B.G.; Kahn, B.B. Protein-tyrosine Phosphatase 1B Expression Is
Induced by Inflammation in Vivo. J. Biol. Chem. 2008, 283, 14230–14241. [CrossRef]
18. Elchebly, M. Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene.
Science 1999, 283, 1544–1548. [CrossRef]
19. Klaman, L.D.; Boss, O.; Peroni, O.D.; Kim, J.K.; Martino, J.L.; Zabolotny, J.M.; Moghal, N.; Lubkin, M.; Kim, Y.-B.; Sharpe, A.H.;
et al. Increased Energy Expenditure, Decreased Adiposity and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase
1B-Deficient Mice. Mol. Cell. Biol. 2000, 20, 5479–5489. [CrossRef]
20. Combs, A.P. Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of
Diabetes, Obesity and Cancer. J. Med. Chem. 2010, 53, 2333–2344. [CrossRef]
21. Lantz, K.A.; Hart, S.G.E.; Planey, S.L.; Roitman, M.F.; Ruiz-White, I.A.; Wolfe, H.R.; McLane, M.P. Inhibition of PTP1B by
Trodusquemine (MSI-1436) Causes Fat-specific Weight Loss in Diet-induced Obese Mice. Obesity 2010, 18, 1516–1523. [CrossRef]
[PubMed]
22. Hidalgo-Figueroa, S.; Estrada-Soto, S.; Ramírez-Espinosa, J.J.; Paoli, P.; Lori, G.; León-Rivera, I.; Navarrete-Vazquez, G. Synthesis
and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B):
Antihyperglycemic activity with molecular docking study. Biomed. Pharmacother. 2018, 107, 1302–1310. [CrossRef] [PubMed]
23. Singh, B.; Silakari, O.; Kaur, M.; Singh, B. Integrated pharmacophore and docking-based designing of dual inhibitors of aldose
reductase (ALR2) and protein tyrosine phosphatase 1B (PTP1B) as novel therapeutics for insulin-resistant diabetes and its
complications. J. Chemom. 2015, 29, 109–125. [CrossRef]
24. Kong, W.-J.; Vernierib, C.; Foiani, M.; Jiang, J. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud
(dCloud) effect to target multifactorial disorders. Pharmacol. Ther. 2020, 209, 107496. [CrossRef] [PubMed]
25. Bruno, G.; Costantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolò, F.; Ottanà, R.; Vigorita, M. Synthesis and aldose reductase
inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorganic Med. Chem. 2002, 10, 1077–1084. [CrossRef]
26. Maccari, R.; Ottanà, R.; Curinga, C.; Vigorita, M.G.; Rakowitz, D.; Steindl, T.; Langer, T. Structure–activity relationships and
molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorganic Med. Chem. 2005, 13,
2809–2823. [CrossRef] [PubMed]
27. Maccari, R.; Ottanà, R.; Ciurleo, R.; Vigorita, M.; Rakowitz, D.; Steindl, T.; Langer, T. Evaluation of in vitro aldose redutase
inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorganic Med. Chem. Lett. 2007, 17, 3886–3893. [CrossRef]
28. Maccari, R.; Ottanà, R.; Ciurleo, R.; Rakowitz, D.; Matuszczak, B.; Laggner, C.; Langer, T. Synthesis, induced-fit docking
investigations and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives.
Bioorganic Med. Chem. 2008, 16, 5840–5852. [CrossRef]
29. Maccari, R.; Ciurleo, R.; Giglio, M.; Cappiello, M.; Moschini, R.; Del Corso, A.; Mura, U.; Ottanà, R. Identification of new
non-carboxylic acid containing inhibitors of aldose reductase. Bioorganic Med. Chem. 2010, 18, 4049–4055. [CrossRef]
30. Ottanà, R.; Maccari, R.; Giglio, M.; Del Corso, A.; Cappiello, M.; Mura, U.; Cosconati, S.; Marinelli, L.; Novellino, E.; Sartini, S.;
et al. Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and
antioxidant agents for the treatment of diabetic complications. Eur. J. Med. Chem. 2011, 46, 2797–2806. [CrossRef]
31. Maccari, R.; Del Corso, A.; Giglio, M.; Moschini, R.; Mura, U.; Ottanà, R. In vitro evaluation of 5-arylidene-2-thioxo-4-
thiazolidinones active as aldose reductase inhibitors. Bioorganic Med. Chem. Lett. 2011, 21, 200–203. [CrossRef] [PubMed]
Molecules 2021, 26, 330 31 of 32
32. Maccari, R.; Vitale, R.M.; Ottanà, R.; Rocchiccioli, M.; Marrazzo, A.; Cardile, V.; Graziano, A.C.E.; Amodeo, P.; Mura, U.; Del
Corso, A. Structure–activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose
reductase inhibitors and potential anti-inflammatory agents. Eur. J. Med. Chem. 2014, 81, 1–14. [CrossRef] [PubMed]
33. Maccari, R.; Paoli, P.; Ottanà, R.; Jacomelli, M.; Ciurleo, R.; Manao, G.; Steindl, T.; Langer, T.; Vigorita, M.G.; Camici, G. 5-
Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorganic Med. Chem. 2007, 15, 5137–5149.
[CrossRef] [PubMed]
34. Ottanà, R.; Maccari, R.; Ciurleo, R.; Paoli, P.; Jacomelli, M.; Manao, G.; Camici, G.; Laggner, C.; Langer, T. 5-Arylidene-2-
phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Bioorganic Med. Chem. 2009, 17, 1928–1937. [CrossRef]
[PubMed]
35. Maccari, R.; Ottanà, R.; Ciurleo, R.; Paoli, P.; Manao, G.; Camici, G.; Laggner, C.; Langer, T. Structure-Based Optimization
of Benzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B and Low Molecular Weight Protein Tyrosine Phosphatase.
ChemMedChem 2009, 4, 957–962. [CrossRef]
36. Ottanà, R.; Maccari, R.; Amuso, S.; Wolber, G.; Schuster, D.; Herdlinger, S.; Manao, G.; Camici, G.; Paoli, P. New 4-[(5-
arylidene-2-arylimino-4-oxo-3-thiazolidinyl)methyl]benzoic acids active as protein tyrosine phosphatase inhibitors endowed
with insulinomimetic effect on mouse C2C12 skeletal muscle cells. Eur. J. Med. Chem. 2012, 50, 332–343. [CrossRef]
37. Ottanà, R.; Maccari, R.; Mortier, J.; Caselli, A.; Amuso, S.; Camici, G.; Rotondo, A.; Wolber, G.; Paoli, P. Synthesis, biological
activity and structure–activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with
insulinomimetic effects in mouse C2C12 skeletal muscle cells. Eur. J. Med. Chem. 2014, 71, 112–127. [CrossRef]
38. Ottanà, R.; Paoli, P.; Naß, A.; Lori, G.; Cardile, V.; Adornato, I.; Rotondo, A.; Graziano, A.C.E.; Wolber, G.; Maccari, R. Discovery
of 4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acid derivatives active as novel potent allosteric inhibitors of protein
tyrosine phosphatase 1B: In silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents. Eur. J. Med.
Chem. 2017, 127, 840–858. [CrossRef]
39. Park, H.; Yu, K.R.; Ku, A.B.; Kim, B.-Y.; Kim, S.J. Identification of novel PTPRQ phosphatase inhibitors based on the virtual
screening with docking simulations. Theor. Biol. Med. Model. 2013, 10, 49. [CrossRef]
40. Liang, D.; Robinson, E.; Hom, K.; Yu, W.; Nguyen, N.; Li, Y.; Zong, Q.; Wilks, A.; Xue, F. Structure-based design and biological
evaluation of inhibitors of the pseudomonas aeruginosa heme oxygenase (pa-HemO). Bioorganic Med. Chem. Lett. 2018, 28,
1024–1029. [CrossRef]
41. Dasgupta, R.; Gonsalves, F. Preparation of substituted oxazole derivatives and analogs for use as beta-catenin modulators. PCT
Int. Appl. 2009, 2009097113.
42. Ottanà, R.; Maccari, R.; Barreca, M.L.; Bruno, G.; Rotondo, A.; Rossi, A.; Chiricosta, G.; Di Paola, R.; Sautebin, L.; Cuzzocrea, S.;
et al. 5-Arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. Bioorganic Med. Chem.
2005, 13, 4243–4252. [CrossRef]
43. Del-Corso, A.; Balestri, F.; Di Bugno, E.; Moschini, R.; Cappiello, M.; Sartini, S.; La-Motta, C.; Da Settimo, F.; Mura, U. A New
Approach to Control the Enigmatic Activity of Aldose Reductase. PLoS ONE 2013, 8, e74076. [CrossRef] [PubMed]
44. Balestri, F.; Quattrini, L.; Coviello, V.; Sartini, S.; Da Settimo, F.; Cappiello, M.; Moschini, R.; Del Corso, A.; Mura, U.; La Motta, C.
Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors. Cell Chem. Biol. 2018, 25, 1414–1418.e3.
[CrossRef]
45. Balestri, F.; Poli, G.; Pineschi, C.; Moschini, R.; Cappiello, M.; Mura, U.; Tuccinardi, T.; Del Corso, A. Aldose Reductase Differential
Inhibitors in Green Tea. Biomolecules 2020, 10, 1003. [CrossRef]
46. Puius, Y.A.; Zhao, Y.; Sullivan, M.; Lawrence, D.S.; Almo, S.C.; Zhang, Z.-Y. Identification of a second aryl phosphate-binding site
in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc. Natl. Acad. Sci. USA 1997, 94, 13420–13425. [CrossRef]
47. Balestri, F.; Cappiello, M.; Moschini, R.; Rotondo, R.; Buggiani, I.; Pelosi, P.; Mura, U.; Del Corso, A. l-Idose: An attractive
substrate alternative to d-glucose for measuring aldose reductase activity. Biochem. Biophys. Res. Commun. 2015, 456, 891–895.
[CrossRef]
48. Balestri, F.; Rotondo, R.; Moschini, R.; Pellegrino, M.; Cappiello, M.; Barracco, V.; Misuri, L.; Sorce, C.; Andreucci, A.; Del Corso,
A.; et al. Zolfino landrace (Phaseolus vulgaris L.) from Pratomagno: General and specific features of a functional food. Food Nutr.
Res. 2016, 60, 31792. [CrossRef]
49. Misuri, L.; Cappiello, M.; Balestri, F.; Moschini, R.; Barracco, V.; Mura, U.; Del Corso, A. The use of dimethylsulfoxide as a solvent
in enzyme inhibition studies: The case of aldose reductase. J. Enzym. Inhib. Med. Chem. 2017, 32, 1152–1158. [CrossRef]
50. Scapin, G.; Patel, S.B.; Becker, J.W.; Wang, Q.; Desponts, C.; Waddleton, D.; Skorey, K.; Cromlish, W.; Bayly, C.; Therien, M.; et al.
The Structural Basis for the Selectivity of Benzotriazole Inhibitors of PTP1B. Biochemistry 2003, 42, 11451–11459. [CrossRef]
51. Zheng, X.; Zhang, L.; Chen, W.; Chen, Y.; Xie, W.; Hu, X. Partial Inhibition of Aldose Reductase by Nitazoxanide and Its Molecular
Basis. ChemMedChem 2012, 7, 1921–1923. [CrossRef] [PubMed]
52. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J.
Mol. Biol. 1997, 267, 727–748. [CrossRef] [PubMed]
53. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening
Filters. J. Chem. Inf. Model. 2005, 45, 160–169. [CrossRef] [PubMed]
54. Wolber, G.; Dornhofer, A.A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput. Mol.
Des. 2006, 20, 773–788. [CrossRef]
Molecules 2021, 26, 330 32 of 32
55. Halgren, T.A. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions.
J. Comput. Chem. 1996, 17, 520–552. [CrossRef]
56. Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC: Montreal, QC, Canada, 2020.
57. Hawkins, P.C.D.; Skillman, A.A.G.; Nicholls, A. Comparison of Shape-Matching and Docking as Virtual Screening Tools. J. Med.
Chem. 2007, 50, 74–82. [CrossRef]
58. Wilson, D.P.; Wan, Z.-K.; Xu, W.-X.; Kirincich, S.J.; Follows, B.C.; Joseph-McCarthy, D.; Foreman, K.; Moretto, A.; Wu, J.; Zhu,
M.; et al. Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second
Phosphotyrosine Binding Site. J. Med. Chem. 2007, 50, 4681–4698. [CrossRef]
